Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 5/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.85 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249713 | 0.95 | HTR1B (0.82) | HTR1BKCNH2MAPTNFKB1NFKB2 | |
| SCHEMBL4248981 | 0.94 | HTR1B (0.84) | HTR1BKCNH2MAPTNFKB1NFKB2 | |
| SCHEMBL4250238 | 0.93 | HTR1B (0.83) | HTR1BKCNH2MAPTNFKB1NFKB2 | |
| SCHEMBL4247047 | 0.92 | HTR1B (1.00) | HTR1BKCNH2MAPTNFKB1NFKB2 | |
| SCHEMBL4247675 | 0.92 | HTR1B (1.00) | HTR1BKCNH2MAPTNFKB1NFKB2 | |
| SCHEMBL14530024 | 0.89 | HTR1B (0.72) | HTR1BKCNH2MAPTNFKB1NFKB2 | |
| SCHEMBL4248608 | 0.89 | HTR1B (0.79) | HTR1BKCNH2MAPTNFKB1NFKB2 | |
| SCHEMBL4246330 | 0.88 | HTR1B (0.93) | HTR1BKCNH2MAPTNFKB1NFKB2 | |
| SCHEMBL4575764 | 0.88 | HTR1B (0.86) | HTR1BKCNH2MAPTNFKB1NFKB2 | |
| SCHEMBL4246219 | 0.87 | HTR1B (0.84) | HTR1BKCNH2MAPTNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945624-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | Astra Zeneca AB (SE) | 2008-07-23 | — | — | EP | claimed |
| US-20070185107-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | claimed |
| US-20070135442-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | claimed |
| WO-2007053095-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | claimed |
| WO-2007053094-A1 | CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | claimed |
| US-20090170851-A1 | Chroman Compounds | BERNSTEIN PETER | 2009-07-02 | — | — | US | disclosed |
| US-20090170851-A1 | Chroman Compounds | BERNSTEIN PETER | 2009-07-02 | — | — | US | disclosed |
| US-20090170851-A1 | Chroman Compounds | BERNSTEIN PETER | 2009-07-02 | — | — | US | disclosed |
| EP-1945624-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | Astra Zeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| US-20070185107-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185107-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185107-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070135442-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| US-20070135442-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| US-20070135442-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| WO-2007053095-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053095-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053094-A1 | CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053094-A1 | CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135442-A1 | Chroman compounds | CYP3A43, CYP2C9, CYP2C8 | HTR1B 592/4885KCNH2 1018/4885MAPT 3096/4885 |
| US-20090170851-A1 | Chroman Compounds | CYP3A43, CYP2C9, CYP2C8 | HTR1B 611/4885KCNH2 1085/4885MAPT 3013/4885 |
| US-20070185107-A1 | Chroman compounds | CYP3A43, CYP2C9, CYP2C8 | HTR1B 611/4885KCNH2 1085/4885MAPT 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.